StreetInsider.com News Articles

Allogene Therapeutics CFO Geoffrey Parker to retire in November

Wed, 02 Sep 2026 08:30:07 -0400

Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026.

Parker will continue to lead the company's finance organization until his retirement date while Allogene conducts an external search for his successor, according to a press release statement.

Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene, commented on Parker's departure: "His financial leadership and commitment to the organization have helped position Allogene to advance our programs with discipline and focus."

Parker said he remains "deeply confident in Allogene's strategy and the potential of its pipeline" and that he

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

Wed, 02 Sep 2026 08:30:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026. Mr. Parker will continue to lead the finance organization through his retirement date as the Company conducts an external search for his successor.

"Geoff has been a trusted and important leader within Allogene through a pivotal period in the Company’s evolution," said Zachary Roberts, M.D.,

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker

Wed, 02 Sep 2026 08:30:00 -0400

"Geoff has been a trusted and important leader within Allogene through a pivotal period in the Company’s evolution," said Zachary Roberts, M.D.,

Allogene Therapeutics Announces Participation in September Investor Conference

Mon, 31 Aug 2026 08:30:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.

Citi Biopharma Back to School Conference
Wednesday, September 9
5:00 a.m. PT/8:00 a.m. ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available

Allogene Therapeutics Announces Participation in September Investor Conference

Mon, 31 Aug 2026 08:30:00 -0400

Citi Biopharma Back to School Conference
Wednesday, September 9
5:00 a.m. PT/8:00 a.m. ET

Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available

Form 4 Allogene Therapeutics, For: Aug 21 Filed by: Douglas Earl Martin

Tue, 25 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260825/26975327.html

Form 4 Allogene Therapeutics, For: Aug 21 Filed by: Douglas Earl Martin

Tue, 25 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260825/26975327.html

Form 144 Allogene Therapeutics, Filed by: Douglas Earl Martin

Fri, 21 Aug 2026 19:27:00 -0400

si-local-file:///var/storage/secattach/20260821/26962738.html

Form 144 Allogene Therapeutics, Filed by: Douglas Earl Martin

Fri, 21 Aug 2026 19:27:00 -0400

si-local-file:///var/storage/secattach/20260821/26962738.html

Form EFFECT Allogene Therapeutics,

Fri, 21 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260821/26958180.html

Form EFFECT Allogene Therapeutics,

Fri, 21 Aug 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260821/26958180.html

Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'

Mon, 17 Aug 2026 04:15:16 -0400

Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $6.00 price target on Allogene (NASDAQ: ALLO).

The analyst commented, "We reiterate our Market Outperform rating for Allogene Therapeutics and our $6 price target based on a discounted EPS and revenue multiples analysis. Recently, Allogene reported 2Q26 earnings and provided operational updates, including that site activation is ahead of schedule and the ALPHA3 trial is on-track for an interim EFS readout in mid-2027. With two assets in the clinic with the potential for valuation driving data read-outs over the next 6-12 months, and a strong cash position of $423.6MM, we view

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Frazier Life Sciences Public Fund, L.P.

Fri, 14 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26931538.html

Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Frazier Life Sciences Public Fund, L.P.

Fri, 14 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26931538.html

Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c

Wed, 12 Aug 2026 16:40:24 -0400

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $4.64 million versus the consensus estimate of $2.22 thousand.

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

Allogene Therapeutics (ALLO) files $500M mixed shelf

Wed, 12 Aug 2026 16:30:19 -0400

Allogene Therapeutics (NASDAQ: ALLO) filed $500,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants

Allogene Therapeutics (ALLO) files $500M mixed shelf

Wed, 12 Aug 2026 16:30:19 -0400

Allogene Therapeutics (NASDAQ: ALLO) filed $500,000,000 mixed shelf of:

Common Stock
Preferred Stock
Debt Securities
Warrants

Form S-3 Allogene Therapeutics,

Wed, 12 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260812/26913295.html

Form S-3 Allogene Therapeutics,

Wed, 12 Aug 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260812/26913295.html

Form 10-Q Allogene Therapeutics, For: Jun 30

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913181.html

Form 10-Q Allogene Therapeutics, For: Jun 30

Wed, 12 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26913181.html

Form 8-K Allogene Therapeutics, For: Aug 12

Wed, 12 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26912977.html

Form 8-K Allogene Therapeutics, For: Aug 12

Wed, 12 Aug 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260812/26912977.html

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 16:05:00 -0400

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL):
- Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy
- Strong Execution and Increased Investigator Interest Accelerated 2026 Site Activation Target by Six Months; Approximately 100 Sites Now Expected by Year-End, Further Supporting Enrollment
- Next Update Anticipated in Mid-2027, with Trial Enrollment Expected to Be Completed by Year-End 2027
- Following Review of the Interim Futility Analysis, FDA Granted RMAT and Fast Track Designations for Cema-Cel Underscoring MRD Positivity as an Unmet Need in LBCL
Phase 1 RESOLUTION Trial in Autoimmune Disease:

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Wed, 12 Aug 2026 16:05:00 -0400

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL):
- Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy
- Strong Execution and Increased Investigator Interest Accelerated 2026 Site Activation Target by Six Months; Approximately 100 Sites Now Expected by Year-End, Further Supporting Enrollment
- Next Update Anticipated in Mid-2027, with Trial Enrollment Expected to Be Completed by Year-End 2027
- Following Review of the Interim Futility Analysis, FDA Granted RMAT and Fast Track Designations for Cema-Cel Underscoring MRD Positivity as an Unmet Need in LBCL
Phase 1 RESOLUTION Trial in Autoimmune Disease: